Pongwut Danchaivijitr

Landscape of industry-sponsored oncology trials across the Thai Society of Clinical Oncology (TSCO): a 12-year multicenter analysis

Kosin Wirasorn, Jirapath Wiwitkeyoonwong, Jitlada Juengsamarn, Chanchai Charonpongsuntorn et autres

Cancer remains a major global health challenge and is a leading cause of morbidity and mortality in Thailand. Industry-sponsored oncology trials (ISOTs) provide critical access to innovative therapies, including targeted agents, immunotherapies (IO), and antibody–drug conjugates (ADCs), particularly in resource-limited settings. We …

th (code pays fourni par la source)

An Observational Study of Afatinib 30 mg Daily in Patients With Advanced Non‐Small‐Cell Lung Cancer Harboring Common EGFR Mutations Treated With Afatinib

Kenneth Sooi, Pongwut Danchaivijitr, C.K. Wong, V. D. Tu et autres

BACKGROUND: Afatinib is an approved first-line treatment for advanced non-small-cell lung cancer (NSCLC) harboring sensitizing EGFR mutations. At the standard 40 mg dose, 28%-53% of patients in randomized trials required dose reductions due to adverse events (AEs), predominantly cutaneous and gastrointestinal. This …

sg, th, my, vn (code pays fourni par la source)

Health-related quality of life (HRQoL) with neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin ineligible: Phase 3 KEYNOTE-905 study.

Peter H. O'Donnell, Nabil Adra, Nimira Alimohamed, Ja Hyeon Ku et autres

4510 Background: In KEYNOTE-905/EV-303 (NCT03924895), neoadj-adj EV + pembro and radical cystectomy (RC) + pelvic lymph node dissection (PLND) showed significant and meaningful improvements in EFS, OS, and pathologic complete response vs RC + PLND in pts with MIBC who were ineligible …

us, ca, kr, th, se, es, ua, de, gb, be (code pays fourni par la source)

Neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants with cisplatin-ineligible muscle-invasive bladder cancer (MIBC): An analysis of clinically relevant subgroups in KEYNOTE-905.

Nabil Adra, Christof Vulsteke, Yohann Loriot, Alejo Rodriguez-Vida et autres

4613 Background: Results from the phase 3 KEYNOTE-905/EV-303 study (NCT03924895) showed that neoadj-adj EV + pembro and radical cystectomy with pelvic lymph node dissection (RC + PLND) led to superior event-free survival (EFS; HR 0.40; 95% CI 0.28-0.57), overall survival (OS; HR …

us, be, fr, es, kr, hu, pl, ua, de, ca, gb, th (code pays fourni par la source)

463P Initial dual tissue-plasma genomic profiling reveals subclonal complexity in advanced non-small cell lung cancer: Evidence from a real-world study in Thailand

Pongwut Danchaivijitr, G. Sittithumcharee, Orawan Suppramote

In advanced non-small cell lung cancer (NSCLC), circulating tumor DNA (ctDNA) analysis is recommended when the standard tissue approach is insufficient or when rapid results are required. Complete genomic coverage by adding liquid biopsy parallel with tissue-based assays to distinguish subclonal architecture …

th (code pays fourni par la source)

Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer

Christof Vulsteke, Nabil Adra, Pongwut Danchaivijitr, М. Є. Сабадаш et autres

BACKGROUND: Patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy proceed directly to radical cystectomy with pelvic lymph-node dissection. Perioperative therapy may improve outcomes in this population. METHODS: In this phase 3, open-label trial, participants with muscle-invasive bladder cancer who …

be, us, th, ua, es, ru, tr, de, kr, fr, ca, pl, jp, se (code pays fourni par la source)

Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis

Hidetoshi Hayashi, Byoung Chul Cho, Yu Jung Kim, Se-Hoon Lee et autres

BACKGROUND: Approximately 60 % of lung cancer cases occur in Asia, indicating an epidemiological disparity and need for effective therapies. Amivantamab-lazertinib is approved for first-line EGFR-mutated advanced non-small cell lung cancer (NSCLC) in many countries. In the protocol-specified final overall survival (OS) …

jp, kr, th, my, cn, tw, tr, in, us (code pays fourni par la source)

PP402 Efficacy and safety of netupitantpalonosetron in colorectal cancer patients receiving moderate-emetogenic chemotherapy: An interim analysis

Pongwut Danchaivijitr, Monson Saritwetworakun, Nuttapat Saengsukkasemsak, Chaloemkiat Leksakorn et autres

th (code pays fourni par la source)

Pan-Asian subgroup analysis of EV-302/KEYNOTE-A39: a phase 3 study to evaluate enfortumab vedotin and pembrolizumab in patients with untreated advanced urothelial carcinoma

Eiji Kikuchi, Michiel S. Van der Heijden, Begona Pérez Valderrama, Shilpa Gupta et autres

BACKGROUND: In the phase 3 EV-302 study, enfortumab vedotin-pembrolizumab (EV + P) significantly prolonged overall survival (OS) and progression-free survival (PFS) versus chemotherapy in patients with untreated locally advanced/metastatic urothelial carcinoma (la/mUC). We present a post hoc analysis in a pan-Asian population. …

jp, nl, es, us, de, kr, tw, cn, th, sg, gb (code pays fourni par la source)

1151P Landscape and performance of industry-sponsored oncology trials in Thailand: A Thai Society of Clinical Oncology (TSCO) multicenter analysis

J. Juengsamarn, Jirapath Wiwitkeyoonwong, Kosin Wirasorn, C. Charonpongsuntorn et autres

th (code pays fourni par la source)

Savolitinib Plus Osimertinib in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trial

James Chih‐Hsin Yang, Yuh‐Min Chen, Ullas Batra, Kien Hung et autres

Background MET amplification is the most common resistance mechanism to first-line osimertinib. We report safety and efficacy data from a phase 2 study assessing savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated, MET-amplified, advanced non-small cell lung cancer (NSCLC). Patients and …

tw, in, vn, th, ar, us, nl, ca (code pays fourni par la source)

Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study

Karim S. Fizazi, Noel William Clarke, Maria De Santis, Hirotsugu Uemura et autres

BACKGROUND: In metastatic hormone-sensitive prostate cancer (mHSPC), phosphatase and tensin homolog (PTEN) deficiency results in phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) pathway activation, providing an independent proliferative drive, which cannot be suppressed by androgen receptor pathway inhibitors (ARPIs), resulting in worse outcomes. …

fr, gb, de, jp, br, tr, pl, es, cn, au, kr, nl, th, us (code pays fourni par la source)